Luteinizing Hormone and Prolactin Response to Buprenorphine in Depression and Schizophrenia
An association of hyper- or hypoactivity of endogenous opioids with depressive and schizophrenic psychoses has, to date, not been convincingly demonstrated. Such an assumption could, however, imply an altered sensitivity of structures involved in the mediation of opioid effects. The effects of opioids on pituitary prolactin (PRL)1,2 and luteinizing hormone (LH) release3,4 in man are well described, and there is little doubt that these effects are mediated through distinct opioid receptor populations. We have demonstrated that the partial opioid agonist buprenorphine exerts both antidepressive and antischizophrenic effects.5 We report here on LH and PRL responses of depressed and schizophrenic patients to acute buprenorphine medication in comparison to respective responses of healthy volunteers.
KeywordsLuteinizing Hormone Schizophrenic Patient Endogenous Opioid Prolactin Response Luteinizing Hormone Release
Unable to display preview. Download preview PDF.
- 3.Delitala G, Devilla L, Arata L. Opiate receptors and anterior pituitary hormone secretion in man: effect of naloxone infusion. Acta Endocrinol (Copenh) 1981; 97: 150–156.Google Scholar
- 5.Schmauss C, Emrich HM. Narcotic antagonist and opioid treatment in psychiatry. In Rodgers RJ, Cooper SJ (eds): Endorphins, Opiates and behavioral Processes. London: Wiley 1987; 327–351.Google Scholar
- 8.Judd LL, Risch S, Parker DC, et al. The effect of methadone challenge on the prolactin and growth hormone responses of psychiatric patients and normal controls. Psychopharmacol Bull 1983; 18: 204–207.Google Scholar